Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-γ dependent

Journal of Immunology

Volumn 169, Issue 10, 2002, Pages 5796-5804

  Ostrand Rosenberg, Suzanne ^a   Clements, Virginia K ^a   Terabe, Masaki ^a   Park, Jong Myun ^a   Berzofsky, Jay A ^a   Dissanayake, Samudra K ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4 RECEPTOR; STAT6 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BREAST CARCINOMA; CANCER SURVIVAL; CELL DIFFERENTIATION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HEMATOPOIETIC CELL; IMMUNITY; IMMUNOSURVEILLANCE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0037111416     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.10.5796     Document Type: Article

References (30)

1. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D, Donaldson, D. Carbone. W. Paul, and J. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immun. 1:515.
2. Kacha, A., F. Fallarino, M. Markiewicz, and T. Gajewski. 2000. Spontaneous rejeciton of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165:6024.
3. Ostrand-Rosenberg, S., M. Grusby, and V. Clements. 2000. Cutting edge: Stat6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:6015.
4. + lymphocytes with a Th2 cytokine profile. J. Immunol. 164:3047.
5. Ohmori. Y., and T. Hamilton. 1998. STAT6 is required for the anti-inflammatory activity of IL-4 in mouse peritoneal macrophages. J. Biol. Chem. 273:29202.
6. Stamm, L., A. Raisanen-Sokolowski, M. Okano, M. Russell, J. David, and A. Satoskar. 1998. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J. Immunol. 161:6180.
7. Shurin, M., L. Lu, P. Kalinski, A. Stewart-Akers, and M. Lotze. 1999. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol. 21:339.
8. + regulatory T cells in anti-tumor therapy reveals alternative pathways for suppression of auto-reactive CTL responses. J. Exp. Med. 194:823.
9. Sakaguchi, S., M. Sakaguchi, M. Asano. M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α chains (CD25): Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
10. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431.
11. + immunoregulatory cells. J. Immunol. 167:1137.
12. Pulaski, B., and S. Ostrand-Rosenberg. 1998. MHC class 11 and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth. Cancer Res. 58:1486.
13. Pulaski, B., D. Terman, S. Khan, E. Muller, and S. Ostrand-Rosenberg. 2000. Cooperativity of SEB superantigen, MHC class 11, and CD80 in immunotherapy of advanced metastases in a clinically relevant post-operative breast cancer model. Cancer Res. 60:2710.
14. Aslakson, C., and F. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1399.
15. + tumor cells with IL-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon-γ. Cancer Immunol. Immunother. 49:34.
16. DeVita, V., S. Hellman, and S. Rosenberg. 2001. Cancer: Principles & Practice of Oncology, 6th Ed. Lippincott-Raven, New York.
17. Kaplan, M., U. Schindler, S. Smiley, and M. Grusby. 1996. STAT6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity 4:313.
18. Seino, K., K. Fukao, K. Muramoto, K. Yanagisawa, Y. Takada, S. Kakuta, Y. Iwakura, L. Van Kaer, K. Takeda, T. Nakayama, et al. 2001. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. USA 98:2577.
19. Mendiratta, S., W. Martin, A. Boesteanu, S. Joyce, and L. Van Kaer. 1997. CDId1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6:469.
20. Pulaski, B., and S. Ostrand-Rosenberg. 2000. Mouse 4T1 breast tumor model. In Current Protocols in Immunology. J. Coligan, D. Margulies, E. Shevach, W. Strober, and A. Kruisbeek, eds. Wiley, Hoboken, NJ, p. 20.2.1.
21. Lowenthal, J., P. Corthesy, C. Tougne, R. Lees, and H. MacDonald. 1985. High and low affinity IL-2 receptors: Analysis by IL-2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 135:3988.
22. Lelekakis, M., J. Moseley, T. Martin, D. Hards, E. Williams, P. Ho, D. Lowen. J. Javni, F. Miller, J. Slavin, and R. Anderson. 1999. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17:163.
23. Miller, F., B. Miller, and G. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: Heterogeneity in phenotypic stability. Invasion Metastasis 3:22.
24. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749.
25. Shtrichman, R., and C. E. Samuel. 2001. The role of γ interferon in antimicrobial immunity. Curr. Opin. Microbiol. 4:251.
26. + effector cells. J. Exp. Med. 159:1295.
27. + T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211.
28. Pulaski, B. A., M. J. Smyth, and S. Ostrand-Rosenberg. 2002. IFNγ-dependent phagocytic cells are a critical component of innate immunity to metastatic mammary carcinoma. Cancer Res. 62:4406.
29. Zurawski, S., F. Vega, B. Huyghe, and G. Zurawski. 1993. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12:2663.
30. Zurawski, S., and J. de Vries. 1994. Interleukin-13, an interleukin-4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 15:19.